Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04059588 · ClinicalTrials.gov registry record · Phase 1
A Study Investigating the Safety and Tolerability of an Immune Treatment in Cancer Patients With Lesions to the Skin
A Phase 1 study, sponsored by Rockefeller University.
- Completed
- Registry status
- Phase 1
- Development phase
- 16
- Enrollment target
NCT04059588 is a Phase 1 study that has completed, run by Rockefeller University. The registered enrollment target is 16 participants.
The verdict
NCT04059588, a Phase 1 study, has completed, sponsored by Rockefeller University.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 16 participants
- Enrollment target
Study Summary
The purpose of this study is to test the safety and tolerability of 2141-V11 in people who have cancer that does not respond to standard treatment and who have skin lesions (skin tumors) associated with their cancer. The study will also test how the body processes and responds to 2141-V11, and if the study drug has cancer fighting activity in people. The study drug activates a naturally occurring protein called CD40. By activating CD40, cells of the immune system are better able to identify and kill cancer cells. We are testing if injection of 2141-V11 into metastasis to the skin will be safe and well tolerated, and may result in immune activation in patients with solid tumors that have metastasis to the skin.
Interventions
- DRUG 2141 V-11
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 16 participants |
| Start Date | 2020-01-16 |
| Est. Completion | 2023-03-13 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04059588
The ClinicalTrials.gov registry entry for NCT04059588 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 16 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Rockefeller University, which has 117 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which 2141 V-11 is the first listed.
NCT04059588 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04059588 about?
NCT04059588 is a clinical study titled "A Study Investigating the Safety and Tolerability of an Immune Treatment in Cancer Patients With Lesions to the Skin". The purpose of this study is to test the safety and tolerability of 2141-V11 in people who have cancer that does not respond to standard treatment and who have skin lesions (skin tumors) associated with their cancer. The study will also test how the body processes and responds to 2141-V11, and if th...
What is the current status of trial NCT04059588?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 16 participants. The study started on 2020-01-16. Estimated completion is 2023-03-13.
What interventions are being tested in trial NCT04059588?
The interventions under investigation include: 2141 V-11 (DRUG).
Who is sponsoring clinical trial NCT04059588?
This trial is sponsored by Rockefeller University, which has 117 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.